Although all subjects lacked nucleocapsid (N) antigen seroreactivity, AIM T cell responses against N peptides were detected in the CD8+ T cells of one healthy control and the CD4+ T cells of three CLL patients, likely representing responses to prior endemic HCoV infections (Table S5B).37, 38 In contrast, overall responses against S peptides were found in 91% of controls, but only 33% of CLL patients (Table S5C). The gene discussed is CD4; the disease is B-cell chronic lymphocytic leukemia.